IPO Grey Market Premium (GMP), Explained

In the weeks before a listing, one number gets quoted more than the issue price itself — the grey market premium, or GMP. WhatsApp groups carry it, finance YouTubers headline it, and retail applicants treat it as a verdict on whether to apply. “GMP is ₹85 over a ₹120 issue price” sounds like a near-guaranteed 70% listing pop. It is not. GMP is an unofficial, unregulated, off-market price set by a handful of operators, and understanding what it actually measures — and what it doesn’t — is essential before any promoter or applicant reads anything into it.

I get this question constantly from founders preparing an SME listing: “What will our GMP be, and can we influence it?” The honest answer involves explaining what the grey market is, who runs it, and why it is the single most misread signal in the Indian primary market. This is that explanation, without the promotion.

What GMP actually is

The grey market premium is the price at which an IPO application — or the shares it is expected to deliver on allotment — changes hands before the shares are officially listed and tradable on the exchange. It is a premium (or, occasionally, a discount) quoted over the issue price. If a share is issued at ₹120 and the GMP is ₹40, the grey market is pricing an expected listing around ₹160.

The word “grey” is precise. This is not a black market — nobody is trading anything illegal in the sense of contraband — but it is not a recognised, regulated market either. There is no exchange, no clearing corporation, no settlement guarantee, no SEBI oversight. Trades are bilateral, settled on trust, and enforced socially rather than legally. The GMP is simply the consensus price that informal dealers are quoting at a given moment. It is sentiment expressed as a rupee figure, nothing more.

Kostak and subject-to-sauda — the two things being traded

The grey market actually deals in two distinct instruments, and confusing them is common. Both let an applicant lock in a gain before listing by selling to an operator who is willing to bet on a higher listing price.

Kostak rate. This is a fixed amount paid to buy a full IPO application — irrespective of whether that application eventually receives an allotment. If the kostak for a retail application is ₹1,200, the applicant sells the application for that flat ₹1,200 and walks away. If allotment comes, the buyer keeps the shares and the listing gain; if it doesn’t, the buyer still paid ₹1,200 for nothing. The applicant has converted an uncertain allotment lottery into a certain (small) cash sum.

Subject-to-sauda rate. This is a deal conditional on allotment — the trade only stands “subject to” the application actually receiving shares. The applicant agrees to sell the allotted shares at a pre-agreed premium per share. No allotment, no deal, no money changes hands. Subject-to-sauda is essentially a forward sale of the expected shares; kostak is a sale of the lottery ticket itself. The headline GMP figure most people quote is the per-share premium, which is closest in spirit to the subject-to-sauda economics.

How it is quoted and who the operators are

GMP is quoted by a small network of unofficial dealers — often concentrated in a few trading hubs in Gujarat and Rajasthan, with Ahmedabad historically a centre — who maintain informal price lists circulated through brokers, sub-brokers and now WhatsApp and Telegram. There is no single authoritative source; the numbers floating across websites and groups are aggregations of what these dealers are reportedly quoting, which is why the same IPO can show three different GMPs at the same time.

The operators run a book. They buy applications and forward-sell shares, hedging their bets across the day as subscription data and broader market mood shift. Their quotes move on supply and demand for the application itself, not on any fresh information about the company. That distinction matters: a rising GMP tells you operators are more eager to buy applications, not that the business got better overnight.

Why it is a sentiment indicator — and nothing more

The most important thing to internalise is that GMP is a measure of demand sentiment for the application, not a valuation of the company. A genuine valuation comes from the fundamentals laid out in the offer document — revenue, margins, the business model, the use of proceeds. GMP comes from how much excitement a few operators are willing to pay for. The two frequently diverge.

For a serious read on whether an issue is fairly priced, the subscription figures published by the exchanges are far more informative than GMP — they are real, official, and show how many times the retail, NII (non-institutional) and QIB (qualified institutional buyer) categories have been bid. A mainboard issue subscribed 50 times in the QIB book is telling you something measurable about institutional appetite. GMP, by contrast, can be a number a handful of dealers chose to quote on thin volume.

If you are a promoter trying to understand the mechanics of your own listing, the structural decisions in my end-to-end SME IPO guide for India will move the needle on outcomes far more than any grey market chatter. GMP is downstream noise; eligibility, pricing and governance are upstream signal.

Why GMP is volatile and easily manipulated

Because the market is thin, opaque and unsettled, GMP swings hard and is trivially gameable. A premium can jump from ₹30 to ₹90 and back to ₹20 inside the three-day subscription window, driven by nothing more than the operators’ reading of the crowd. There is no order book to inspect, no volume to verify, and no regulator watching — so a quoted number can be inflated deliberately.

The manipulation incentive is real. An operator (or an interested party) who wants to whip up retail frenzy can leak an artificially high GMP into the WhatsApp ecosystem, drive oversubscription, and then let the premium collapse once the subscription numbers are locked. This is especially pronounced in smaller SME issues, where the float is tiny and a handful of quotes can set the entire perceived premium. The choice of platform and the size of the issue shape how thin that grey market is — something I cover when comparing BSE SME against NSE Emerge. The smaller and more illiquid the post-listing float, the more violently both GMP and the actual listing price tend to move.

The regulatory and legal grey zone

GMP is not recognised by SEBI, BSE or NSE in any official capacity. You will not find it in the offer document, the listing circular or any exchange disclosure. The primary market framework — pricing, allotment basis, the role of the merchant banker, mandatory disclosures — is governed by the SEBI ICDR Regulations, and none of it contemplates a grey market premium. The official process ends at a transparent, regulated allotment; the grey market sits entirely outside it.

The trades themselves occupy an awkward legal space. They are off-market dealings in securities (or rights to securities) that are settled informally, with no contracts that a court would readily enforce. There is no investor-protection mechanism: if an operator defaults on a subject-to-sauda after a poor listing, the applicant has no recourse. Promoters in particular should keep a clear distance — being seen to engage with or influence grey market activity around your own issue is precisely the kind of conduct that draws regulatory scrutiny and damages credibility with the institutional investors who actually matter for a clean book.

How promoters should read it

For a promoter, GMP is a thermometer, not a target. A buoyant grey market before your issue opens can indicate retail enthusiasm, which helps the retail subscription category — but it tells you nothing reliable about the durability of your share price three months out, and chasing it is a mistake. The post-listing reality is set by your fundamentals, your free float, your investor communication and broader market conditions, not by a pre-listing premium that evaporates on day one.

The disciplined approach is to ignore GMP as a planning input entirely and focus on the controllable levers: a defensible issue price, a credible use-of-proceeds story, clean financials, and the right intermediaries. The economics that genuinely determine whether your listing is a success — and what it costs to get there — are laid out in my breakdown of SME IPO cost and the real timeline. Spend your attention there, not on the grey market ticker.

How retail investors should read it

For an applicant, the rule is simple: never apply to an IPO on the strength of GMP alone. A high premium is not a guarantee of a listing pop, and it is certainly not a substitute for reading the offer document. Plenty of issues with eye-watering grey market premiums have listed flat or below issue price once the enthusiasm met reality; plenty with modest GMP have held up because the underlying business was sound.

Treat GMP, at most, as one weak sentiment data point among many — and weigh it well below the things that are real and verifiable: the subscription figures, the financials, the promoter track record, the valuation relative to listed peers, and the use of proceeds. The governance and structuring work that separates a durable listing candidate from a pump-and-dump is the same work I describe in the 18-month pre-IPO structuring runway and in the section-by-section DRHP walkthrough. A premium quoted by an anonymous dealer on WhatsApp is not part of that analysis.

Bottom line

Grey market premium is an unofficial, unregulated, off-market price for IPO applications and expected shares, traded through kostak and subject-to-sauda arrangements by a small network of operators with no exchange, no settlement guarantee and no SEBI recognition behind them. It measures short-term demand sentiment for an application — not the value of the company, not a forecast you can rely on, and certainly not a guarantee of listing gains. It is volatile, thin and easy to manipulate, particularly on small SME issues. Read it, if at all, as one fragile mood reading. Then set it aside and make the decision — to issue or to apply — on the fundamentals, the subscription data and the disclosures that are actually real.